

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

NCT05626530

Status	RECRUITING
Phase	Phase 4
Sponsor	Tufts Medical Center
Enrollment	25 participants

Key Eligibility Criteria

Inclusion (3)

- Adult (> 18 years old) solid organ transplant recipients (heart, kidney or liver patients) recovering from treated CMV disease in whom the clinician deems that the patient need secondary prophylaxis and in whom written informed consent is obtained.
- Patient able to participate with follow up for 6 months
- Not enrolled in competing clinical trials

Exclusion (15)

- Patients with creatinine clearance less than 10 ml per min at time of enrollment
 - Hypersensitivity to letermovir or has a CMV isolate which is known to be resistant to letermovir based on prior testing
 - On CVVH or renal dialysis at the time of enrollment
 - Has Child Pugh Class C severe hepatic insufficiency at screening.
 - Has both moderate hepatic insufficiency AND moderate to severe renal insufficiency at screening.
- ... and 10 more (see full listing online)

Locations (1 total)

Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases, Boston, Massachusetts, United States